Teduglutide for pediatric short bowel syndrome patients

References

• Martin GR, Wallace LE, Hartmann B, et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2005;288(3):G431–8.
   PubMed Web of Science ®Google Scholar
• Squires RH, Duggan C, Teitelbaum DH, et al. Natural history of pediatric intestinal failure: initial report from the pediatric intestinal failure consortium. J Pediatr. 2012;161(4):723–8.e2.
   PubMed Web of Science ®Google Scholar
• Castillo RO, Feng JJ, Stevenson DK, et al. Altered maturation of small intestinal function in the absence of intraluminal nutrients: rapid normalization with refeeding. Am J Clin Nutr. 1991;53(2):558–561.
   PubMed Web of Science ®Google Scholar
• Stanger JD, Oliveira C, Blackmore C, et al. The impact of multi-disciplinary intestinal rehabilitation programs on the outcome of pediatric patients with intestinal failure: a systematic review and meta-analysis. J Pediatr Surg. 2013;48(5):983–992.
   PubMed Web of Science ®Google Scholar
• Fullerton BS, Sparks EA, Hall AM, et al. Enteral autonomy, cirrhosis, and long term transplant-free survival in pediatric intestinal failure patients. J Pediatr Surg. 2016;51(1):96–100.
   PubMed Web of Science ®Google Scholar
• Nehra V, Camilleri M, Burton D, et al. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol. 2001;96(5):1494–1498.
   PubMed Web of Science ®Google Scholar
• Byrne TA, Wilmore DW, Iyer K, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg. 2005;242(5):655–661.
   PubMed Web of Science ®Google Scholar
• Duggan C, Stark AR, Auestad N, et al. Glutamine supplementation in infants with gastrointestinal disease: a randomized, placebo-controlled pilot trial. Nutrition. 2004;20(9):752–756.
   PubMed Web of Science ®Google Scholar
• Shamir R, Kolacek S, Koletzko S, et al. Oral insulin supplementation in paediatric short bowel disease: a pilot observational study. J Pediatr Gastroenterol Nutr. 2009;49(1):108–111.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Gut adaptation and the glucagon-like peptides. Gut. 2002;50(3):428–435.
   PubMed Web of Science ®Google Scholar
• Shire-NPS Pharmaceuticals Inc. Gattex (teduglutide) for injection [package insert]. U.S. Food and Drug Administration. Revised 2019. [cited 2021].Available from: www.accessdata.fda.gov
   Google Scholar
• Kim ES, Keam SJ. Teduglutide: a review in short bowel syndrome. Drugs. 2017;77(3):345–352.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902–914.
   PubMed Web of Science ®Google Scholar
• Jeppesen P, Sanguinetti E, Buchman A et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005 Sep;54(9):1224–1231
   PubMed Web of Science ®Google Scholar
• Thymann T, Stoll B, Mecklenburg L, et al. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr Gastroenterol Nutr. 2014;58(6):694–702. .
   PubMed Web of Science ®Google Scholar
• Yusta B, Holland D, Koehler J, et al. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology. 2009 Sep;137(3):986–996. .
   PubMed Web of Science ®Google Scholar
• Carter BA, Cohran VC, Cole CR, et al. Outcomes from a 12-week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome. J Pediatr. 2017;181:102–11.e5.
   PubMed Web of Science ®Google Scholar
• Teduglutide. lexicomp online, pediatric and neonatal lexi-drugs online, hudson, ohio: Wolters Kluwer Clinical Drug Information.; 2013 Dec 13, 2020. Available at: http://online.lexi.com.
   Google Scholar
• Ferrone MSJ, Scolapio JS. Teduglutide for the treatment of short bowel syndrome. Ann Pharmacother. 2006;40(6):1105–1109.
   PubMed Web of Science ®Google Scholar
• Kocoshis SA, Merritt RJ, Hill S, et al., Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: a 24-week, phase iii study. JPEN J Parenter Enteral Nutr. 44(4): 621–631. 2020. .
   PubMed Web of Science ®Google Scholar
• Tappenden K, Edelman J, Joelsson B. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol. 2013;47(7):602–607.
   PubMed Web of Science ®Google Scholar
• Seidner DL, Joly F, Youssef NN. Effect of teduglutide, a glucagon-like peptide 2 analog, on citrulline levels in patients with short bowel syndrome in two phase iii randomized trials. Clin Transl Gastroenterol. 2015;6(6):93–95.
   Google Scholar
• Teduglutide. micromedex® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA.; Feb 2021; 2021 Feb 20. Available at: https://www.micromedexsolutions.com/.
   Google Scholar
• Jeppesen P, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012 Dec;143(6):1473–1481.e3.
   PubMed Web of Science ®Google Scholar
• Seidner D, Fujioka K, Boullata J, et al. Reduction of parenteral nutrition and hydration support and safety with long-term teduglutide treatment in patients with short bowel syndrome-associated intestinal failure: steps-3 study. Nutr Clin Pract. 2018 Aug;33(4):520–527.
   PubMed Web of Science ®Google Scholar
• O’Keefe S, Jeppesen P, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013 Jul;11(7):815–823.
   PubMed Web of Science ®Google Scholar
• Shire Internal Data. (SHP633-303). Unpublished Internal CSR Source Data. Shire-NPS Pharmaceuticals, Inc. 2017.
   Google Scholar
• Ramos Boluda E, Redecillas Ferreiro S, Manrique Moral O, et al. Experience with teduglutide in pediatric short bowel syndrome: first real-life data. J Pediatr Gastroenterol Nutr. 2020 Dec;71(6):734–739.
   PubMed Web of Science ®Google Scholar
• Hansen N, Brønden A, Nexøe-Larsen C, et al. Glucagon-like peptide 2 inhibits postprandial gallbladder emptying in man: a randomized, double-blinded, crossover study, clinical and translational gastroenterology. Gastroenterology. 2020 Dec;11(12):2463–2472. December 2020 - Volume 11 - Issue 12 - p e00257.
   Web of Science ®Google Scholar
• Hill S, Carter B, Cohran V, et al. Safety findings in pediatric patients during long-term treatment with teduglutide for short bowel syndrome-associated intestinal failure: pooled analysis of four clinical studies. JPEN J Parenter Enteral Nutr. 2020 Dec. DOI: 10.1002/jpen.2061 Epub ahead of print. PMID 33305440.
   Web of Science ®Google Scholar
• Wilmore DW. Factors correlating with a successful outcome following extensive intestinal resection in newborn infants. J Pediatr. 1972;80(1):88–95.
   PubMed Web of Science ®Google Scholar
• Raghu VK, Beaumont JL, Everly MJ, et al. Pediatric intestinal transplantation: analysis of the intestinal transplant registry. Pediatr Transplant. 2019;23(8): Epub 2019 Sep 18. DOI: 10.1111/petr.13580.
   PubMed Web of Science ®Google Scholar
• Varga J, Toth S, Stasko P, et al. Different ischemic preconditional regimens affecting preservation injury of intestines. Eur Surg Res. 2011;46(4):207–213.
   PubMed Web of Science ®Google Scholar
• Fishbein T, Novitskiy G, Lough D, et al. Rejection reversibly alters enteroendocrine cell renewal in the transplanted small intestine. Am J Transplant. 2009;9(7):1620–1628.
   PubMed Web of Science ®Google Scholar
• Hvistendahl M, Naimi R, Enevoldsen L, et al. Hvistendahl MK, Naimi RM, Enevoldsen LH, Madsen JL, Fuglsang S, Jeppesen PB.Effect of glepaglutide, a long-acting glucagon-like peptide-2 analog, on gastrointestinal transit time and motility in patients with short bowel syndrome: findings from a randomized trial. JPEN J Parenter Enteral Nutr. 2020 Nov;44(8):1535–1544. .
   PubMed Web of Science ®Google Scholar
• Slim G, Lansing M, Wizzard P, et al. Novel long-acting GLP-2 analogue, FE 203799 (apraglutide), enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum. JPEN J Parenter Enteral Nutr. 2019 Sep;43(7):891–898.
   PubMed Web of Science ®Google Scholar
• Wismann P, Pedersen SL, Hansen G, et al. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. Physio Behav. 2018;192(72):72–81.
   PubMedGoogle Scholar
• Hvistendahl M, Brandt C, Tribler S, et al. Effect of liraglutide treatment on jejunostomy output in patients with short bowel syndrome: an open-label pilot study. JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):112–121.
   PubMed Web of Science ®Google Scholar